Immune checkpoint inhibition for the treatment of metastatic breast cancer with high tumor mutational burden: Real world clinical and genomic correlates of response

被引：0
|
作者：
Mai, Nicholas
Safonov, Anton
Marra, Antonio
Chen, Yuan
Chandarlapaty, Sarat
Razavi, Pedram
Plitas, George
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] European Inst Oncol IRCCS, Div Early Drug Dev, Milan, Italy
[3] Mem Sloan Kettering Canc Ctr, Dept Surg, Breast Serv, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1078
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Frequency and mechanisms of elevated somatic mutation burden in metastatic breast cancer and response to immune checkpoint blockade
    Cobain, Erin F.
    Robinson, Dan R.
    Wu, Yi-Mi
    Lonigro, Robert
    Vats, Punkaj
    Rabban, Erica
    Kumar-Sinha, Chandan
    Schott, Anne F.
    Smerage, Jeffrey B.
    Morikawa, Aki
    Burness, Monika L.
    Van Poznak, Catherine H.
    Griggs, Jennifer
    Wicha, Max
    Hayes, Daniel F.
    Chinnaiyan, Arul M.
    CANCER RESEARCH, 2018, 78 (04)
  • [32] Efficacy of pembrolizumab in microsatellite-stable, tumor mutational burden-high metastatic colorectal cancer: genomic signatures and clinical outcomes
    Yamaguchi, K.
    Tsuchihashi, K.
    Ueno, S.
    Uehara, K.
    Taguchi, R.
    Ito, M.
    Isobe, T.
    Imajima, T.
    Kitazono, T.
    Tanoue, K.
    Ohmura, H.
    Akashi, K.
    Baba, E.
    ESMO OPEN, 2025, 10 (01)
  • [33] Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer
    Sammons, Sarah
    Elliott, Andrew
    Barroso-Sousa, Romualdo
    Chumsri, Saranya
    Tan, Antoinette R.
    Sledge, George W.
    Tolaney, Sara M.
    Torres, Evanthia T. Roussos
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [34] Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer
    Sammons, Sarah
    Elliott, Andrew
    Force, Jeremy
    Chumsri, Saranya
    Anders, Carey
    Tan, Antoinette R.
    Magee, Daniel
    Zeng, Jia
    Korn, W. Michael
    Kahsraw, Mustafa
    Torres, Evanthia T. Roussos
    CANCER RESEARCH, 2022, 82 (04)
  • [35] Tumor mutational burden (TMB) as a predictive biomarker of immune checkpoint blockade (ICB) in metastatic solid tumors
    Kao, Chester
    Powers, Eric
    Datto, Michael B.
    Green, Michelle
    Harrison, Michael Roger
    Armstrong, Andrew J.
    George, Daniel J.
    Clarke, Jeffrey Melson
    Strickler, John H.
    Zhang, Tian
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (05)
  • [36] Comprehensive genomic analysis reveals molecular correlates of response to immune checkpoint inhibitors (ICI) in metastatic triple-negative breast cancer (mTNBC)
    Barroso-Sousa, Romualdo
    Forman, Juliet
    Weber, Zachary T.
    Collier, Katherine
    Kao, Katrina Z.
    Richardson, Edward T., III
    Keenan, Tanya
    Cohen, Ofir
    Manos, Michael P.
    Brennick, Ryan C.
    Ott, Patrick
    Hodi, F. Steve
    Dillon, Deborah A.
    Lin, Nancy U.
    Van Allen, Eliezer E.
    Rodig, Scott
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Wu, Catherine J.
    Stover, Daniel
    Wagle, Nikhil
    Shukla, Sachet
    Tolaney, Sara
    CANCER RESEARCH, 2021, 81 (04)
  • [37] Penile squamous cell carcinoma with high and very high tumor mutational burden (TMB): A genomic landscape and "real-world" clinical outcome study
    Jacob, J. M.
    Spiess, P.
    Padua, T. C. D.
    Li, R.
    Grivas, P.
    Huang, R.
    Lin, D. I.
    Danziger, N. A.
    Ross, J. S.
    Li, G.
    Graf, R. P.
    Pavlick, D. C.
    Basnet, A.
    Bratslavsky, G.
    Necchi, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S506 - S506
  • [38] Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer
    Graf, Ryon P.
    Fisher, Virginia
    Weberpals, Janick
    Gjoerup, Ole
    Tierno, Marni B.
    Huang, Richard S. P.
    Sayegh, Nicolas
    Lin, Douglas, I
    Raskina, Kira
    Schrock, Alexa B.
    Severson, Eric
    Haberberger, James F.
    Ross, Jeffrey S.
    Creeden, James
    Levy, Mia A.
    Alexander, Brian M.
    Oxnard, Geoffrey R.
    Agarwal, Neeraj
    JAMA NETWORK OPEN, 2022, 5 (03)
  • [39] Tumor mutational burden as a predictive biomarker for immune checkpoint inhibitor versus taxane chemotherapy benefit in metastatic castration-resistant prostate cancer: A real-world biomarker study.
    Sayegh, Nicolas
    Graf, Ryon
    Fisher, Virginia
    Weberpals, Janick
    Huang, Richard S. P.
    Lin, Douglas I.
    Gjoerup, Ole
    Raskina, Kira
    Severson, Eric Allan
    Haberberger, James
    Ross, Jeffrey S.
    Alexander, Brian Michael
    Levy, Mia Alyce
    Oxnard, Geoffrey R.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [40] Clinical and Genomic Factors Associated with Greater Tumor Mutational Burden in Prostate Cancer
    Hougen, Helen Y.
    Graf, Ryon P.
    Li, Gerald
    Quintanilha, Julia C. F.
    Lin, Douglas I.
    Ross, Jeffrey S.
    Punnen, Sanoj
    Mahal, Brandon A.
    EUROPEAN UROLOGY OPEN SCIENCE, 2023, 55 : 45 - 49
12345